Letter to AB Science stakeholders on COVID-19 pandemic impact on AB Science clinical studies
April 07, 2020 12:33 ET
|
AB Science
Paris, April 07, 2020, 6.15pm A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies Dear Stakeholders, At this time, we expect that the COVID-19 pandemic will have...
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 26, 2020 16:07 ET
|
Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 13, 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
AB Science fournit le résumé de la conférence web avec les principaux leaders d’opinion autour des résultats de la phase 3 du masitinib dans l’asthme sévère
December 02, 2019 16:31 ET
|
AB Science
Paris, 2 décembre 2019, 22h15 Résumé de la conférence web avec les principaux leaders d’opinion autourdes résultats de la phase 3 du masitinib dans l’asthme sévère non contrôlé par les...
AB Science provides the summary of webcast with Key Opinion Leaders on masitinib Phase 3 results in severe asthma uncontrolled by oral corticosteroids
December 02, 2019 16:31 ET
|
AB Science
Paris, 02 December 2019, 10.15pm Summary of webcast with Key Opinion Leaders on masitinibPhase 3 results in severe asthma uncontrolled by oral corticosteroids AB Science SA (NYSE Euronext -...
Equillium to Host Business Update Call on October 1, 2019
September 17, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
August 27, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
July 10, 2019 08:07 ET
|
Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Jefferies 2019 Healthcare Conference
May 23, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Expands Scientific and Clinical Advisory Team
May 06, 2019 08:30 ET
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...